Literature DB >> 32636266

Antiresorptive activity of osteoprotegerin requires an intact heparan sulfate-binding site.

Miaomiao Li1, Ding Xu2.   

Abstract

Osteoprotegerin (OPG), a secreted decoy receptor for receptor activator of nuclear factor B ligand (RANKL), plays an essential role in regulating bone resorption. While much is known about the function of the N-terminal domains of OPG, which is responsible for binding to RANKL, the exact biological functions of the three C-terminal domains of OPG remain uncertain. We have previously shown that one likely function of the C-terminal domains of OPG is to bind cell surface heparan sulfate (HS), but the in vivo evidence was lacking. To investigate the biological significance of OPG-HS interaction in bone remodeling, we created OPG knock-in mice (opg AAA ). The mutated OPG is incapable of binding to HS but binds RANKL normally. Surprisingly, opg AAA/AAA mice displayed a severe osteoporotic phenotype that is very similar to opg-null mice, suggesting that the antiresorption activity of OPG requires HS. Mechanistically, we propose that the HS immobilizes secreted OPG at the surface of osteoblasts lineage cells, which facilitates binding of OPG to membrane-anchored RANKL. To further support this model, we altered the structure of osteoblast HS genetically to make it incapable of binding to OPG. Interestingly, osteocalcin-Cre;Hs2st f/f mice also displayed osteoporotic phenotype with similar severity to opg AAA/AAA mice. Combined, our data provide strong genetic evidence that OPG-HS interaction is indispensable for normal bone homeostasis.

Entities:  

Keywords:  H2st; OPG; RANKL; heparan sulfate; osteoclast

Mesh:

Substances:

Year:  2020        PMID: 32636266      PMCID: PMC7382260          DOI: 10.1073/pnas.2005859117

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  29 in total

1.  Crystal structure of human RANKL complexed with its decoy receptor osteoprotegerin.

Authors:  Xudong Luan; Qingyu Lu; Yinan Jiang; Senyan Zhang; Qing Wang; Huihui Yuan; Wenming Zhao; Jiawei Wang; Xinquan Wang
Journal:  J Immunol       Date:  2012-06-04       Impact factor: 5.422

2.  RANKL inhibition improves muscle strength and insulin sensitivity and restores bone mass.

Authors:  Nicolas Bonnet; Lucie Bourgoin; Emmanuel Biver; Eleni Douni; Serge Ferrari
Journal:  J Clin Invest       Date:  2019-05-23       Impact factor: 14.808

3.  Novel heparan sulfate structures revealed by monoclonal antibodies.

Authors:  Jacob van den Born; Katriina Salmivirta; Tiina Henttinen; Nina Ostman; Takeshi Ishimaru; Shuichi Miyaura; Keiichi Yoshida; Markku Salmivirta
Journal:  J Biol Chem       Date:  2005-03-18       Impact factor: 5.157

4.  Mice deficient in heparan sulfate 6-O-sulfotransferase-1 exhibit defective heparan sulfate biosynthesis, abnormal placentation, and late embryonic lethality.

Authors:  Hiroko Habuchi; Naoko Nagai; Noriko Sugaya; Fukiko Atsumi; Richard L Stevens; Koji Kimata
Journal:  J Biol Chem       Date:  2007-04-03       Impact factor: 5.157

5.  Osteoprotegerin protects against muscular dystrophy.

Authors:  Sébastien S Dufresne; Nicolas A Dumont; Patrice Bouchard; Éliane Lavergne; Josef M Penninger; Jérôme Frenette
Journal:  Am J Pathol       Date:  2015-02-21       Impact factor: 4.307

6.  Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL.

Authors:  H Yasuda; N Shima; N Nakagawa; K Yamaguchi; M Kinosaki; S Mochizuki; A Tomoyasu; K Yano; M Goto; A Murakami; E Tsuda; T Morinaga; K Higashio; N Udagawa; N Takahashi; T Suda
Journal:  Proc Natl Acad Sci U S A       Date:  1998-03-31       Impact factor: 11.205

7.  Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin.

Authors:  A Mizuno; N Amizuka; K Irie; A Murakami; N Fujise; T Kanno; Y Sato; N Nakagawa; H Yasuda; S Mochizuki; T Gomibuchi; K Yano; N Shima; N Washida; E Tsuda; T Morinaga; K Higashio; H Ozawa
Journal:  Biochem Biophys Res Commun       Date:  1998-06-29       Impact factor: 3.575

8.  Dimerization interface of osteoprotegerin revealed by hydrogen-deuterium exchange mass spectrometry.

Authors:  Yiming Xiao; Miaomiao Li; Rinzhi Larocque; Fuming Zhang; Anju Malhotra; Jianle Chen; Robert J Linhardt; Lars Konermann; Ding Xu
Journal:  J Biol Chem       Date:  2018-09-25       Impact factor: 5.157

9.  Osteoblastic heparan sulfate regulates osteoprotegerin function and bone mass.

Authors:  Satoshi Nozawa; Toshihiro Inubushi; Fumitoshi Irie; Iori Takigami; Kazu Matsumoto; Katsuji Shimizu; Haruhiko Akiyama; Yu Yamaguchi
Journal:  JCI Insight       Date:  2018-02-08

10.  A therapeutic antibody targeting osteoprotegerin attenuates severe experimental pulmonary arterial hypertension.

Authors:  Nadine D Arnold; Josephine A Pickworth; Laura E West; Sarah Dawson; Joana A Carvalho; Helen Casbolt; Adam T Braithwaite; James Iremonger; Lewis Renshall; Volker Germaschewski; Matthew McCourt; Philip Bland-Ward; Hager Kowash; Abdul G Hameed; Alexander M K Rothman; Maria G Frid; A A Roger Thompson; Holly R Evans; Mark Southwood; Nicholas W Morrell; David C Crossman; Moira K B Whyte; Kurt R Stenmark; Christopher M Newman; David G Kiely; Sheila E Francis; Allan Lawrie
Journal:  Nat Commun       Date:  2019-11-15       Impact factor: 14.919

View more
  4 in total

1.  The heparan sulfate proteoglycan Syndecan-1 influences local bone cell communication via the RANKL/OPG axis.

Authors:  Melanie Timmen; Heriburg Hidding; Martin Götte; Thaqif El Khassawna; Daniel Kronenberg; Richard Stange
Journal:  Sci Rep       Date:  2020-11-25       Impact factor: 4.379

Review 2.  Small leucine-rich proteoglycans in physiological and biomechanical function of bone.

Authors:  Rui Hua; Jean X Jiang
Journal:  Matrix Biol Plus       Date:  2021-05-06

3.  Biochemical characterization of a disease-causing human osteoprotegerin variant.

Authors:  Yin Luo; Miaomiao Li; Ding Xu
Journal:  Sci Rep       Date:  2022-09-10       Impact factor: 4.996

4.  Bi-directional regulation functions of lanthanum-substituted layered double hydroxide nanohybrid scaffolds via activating osteogenesis and inhibiting osteoclastogenesis for osteoporotic bone regeneration.

Authors:  Min Chu; Zhenyu Sun; Zhanghao Fan; Degang Yu; Yuanqing Mao; Yaping Guo
Journal:  Theranostics       Date:  2021-05-03       Impact factor: 11.556

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.